Bioventus Inc. (BVS) News
Filter BVS News Items
BVS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BVS News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest BVS News From Around the Web
Below are the latest news stories about BIOVENTUS INC that investors may wish to consider to help them evaluate BVS as an investment opportunity.
Bioventus to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceDURHAM, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 10:30 a.m. PT (1:30 p.m. ET). The live webcast of the presentation, including Q&A, may be accessed on the Investors section of the Bioventus website and will be available until February 15, 2025. About Biovent |
BVS Stock Gains Post Divestiture of Advanced Rehabilitation BusinessBioventus aims to improve its focus and execution within its core businesses and enhance liquidity following the divestiture. |
Bioventus completes divestiture of its Advanced Rehabilitation businessBioventus (BVS) announced that it has successfully completed the divestiture of its Advanced Rehabilitation business to Accelmed Partners, a private equity firm focused on acquiring and growing commercial-stage HealthTech companies. The transaction, announced on October 1, 2024, enables Bioventus to continue improving its focus and execution within the Company’s core businesses, while also delivering approximately $20 million of net closing proceeds to enhance liquidity. Published first on TheFl |
Bioventus Completes Divestiture of its Advanced Rehabilitation Business to Accelmed PartnersDURHAM, N.C., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has successfully completed the divestiture of its Advanced Rehabilitation business to Accelmed Partners (“Accelmed”), a private equity firm focused on acquiring and growing commercial-stage HealthTech companies. The transaction, announced on October 1, 2024, enables Bioventus to continue improving its focus and exe |
Is Bioventus (BVS) Outperforming Other Medical Stocks This Year?Here is how Bioventus (BVS) and Adagene Inc. Sponsored ADR (ADAG) have performed compared to their sector so far this year. |
Wall Street Analysts Think Bioventus (BVS) Could Surge 26.03%: Read This Before Placing a BetThe average of price targets set by Wall Street analysts indicates a potential upside of 26% in Bioventus (BVS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
Q3 2024 Bioventus Inc Earnings CallQ3 2024 Bioventus Inc Earnings Call |
Bioventus Inc (BVS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance ...Bioventus Inc (BVS) reports a 15% revenue increase and raises full-year guidance, while addressing market challenges and strategic growth initiatives. |
Bioventus (BVS) Matches Q3 Earnings EstimatesBioventus (BVS) delivered earnings and revenue surprises of 0% and 4.82%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
Bioventus: Q3 Earnings SnapshotDURHAM, N.C. (AP) — Bioventus Inc. BVS) on Tuesday reported a loss of $4.8 million in its third quarter. On a per-share basis, the Durham, North Carolina-based company said it had a loss of 7 cents. |